Background and Objective: The treatment of COVID19 has presented new challenges to global public health, and a large number of therapeutic drugs are employed for their treatment. However, there is limited data comparing the efficacy of available drugs with Traditional Chinese Medicine (TCM). Aim of this research was to compare the usefulness of monotherapies with Azvudine (FNC) or Qingfei Paidu Decoction (QFPD) or in combination with FNC and QFPD for mild and moderate COVID-19. Methods: A retrospective analysis was conducted on data from a public hospital in Zibo City, China, including confirmed mild and moderate COVID-19 cases. Patients were categorized into three treatment groups: (i) FNC monotherapy, (ii) QFPD monotherapy, and (iii) FNC + QFPD combination therapy. Results: A total of 300 cases were analyzed, with a mean age of 61.3 ± 7.18 years. Males (n=165, 55.0%) slightly outnumbered females (n=135, 45.0%). The shortest duration of negative nucleic acid conversion (NANC) was observed in the combination therapy group (8.58 ± 2.64 days, p < 0.001). Hospital stay was also significantly shorter (12.23 ± 3.52 days, p < 0.001). The combination therapy group showed the highest effective rates for pulmonary lesion absorption (97%) and clinical efficacy (95%), with a significant improvement in TCM symptom scores (2.24 ± 0.43, p < 0.001). Conclusion: FNC combined with QFPD demonstrated significant clinical efficacy in treating mild and moderate COVID-19, warranting further large-scale studies and clinical applications.